BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16260184)

  • 1. The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion.
    Nam CH; Rabbitts TH
    Mol Ther; 2006 Jan; 13(1):15-25. PubMed ID: 16260184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development.
    McCormack MP; Forster A; Drynan L; Pannell R; Rabbitts TH
    Mol Cell Biol; 2003 Dec; 23(24):9003-13. PubMed ID: 14645513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal translocations and leukaemia: a role for LMO2 in T cell acute leukaemia, in transcription and in erythropoiesis.
    Rabbitts TH; Axelson H; Forster A; Grutz G; Lavenir I; Larson R; Osada H; Valge-Archer V; Wadman I; Warren A
    Leukemia; 1997 Apr; 11 Suppl 3():271-2. PubMed ID: 9209362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
    Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA
    Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis.
    Yamada Y; Warren AJ; Dobson C; Forster A; Pannell R; Rabbitts TH
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3890-5. PubMed ID: 9520463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LMO2 at 25 years: a paradigm of chromosomal translocation proteins.
    Chambers J; Rabbitts TH
    Open Biol; 2015 Jun; 5(6):150062. PubMed ID: 26108219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
    Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
    PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.
    Yamada Y; Pannell R; Forster A; Rabbitts TH
    Proc Natl Acad Sci U S A; 2000 Jan; 97(1):320-4. PubMed ID: 10618416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of chromosomal translocations in acute leukemias: the LMO2 paradigm in transcription and development.
    Rabbitts TH; Bucher K; Chung G; Grutz G; Warren A; Yamada Y
    Cancer Res; 1999 Apr; 59(7 Suppl):1794s-1798s. PubMed ID: 10197599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice.
    Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH
    EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
    Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
    Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The LIM-domain binding protein Ldb1 and its partner LMO2 act as negative regulators of erythroid differentiation.
    Visvader JE; Mao X; Fujiwara Y; Hahm K; Orkin SH
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13707-12. PubMed ID: 9391090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.
    El Omari K; Hoosdally SJ; Tuladhar K; Karia D; Vyas P; Patient R; Porcher C; Mancini EJ
    Blood; 2011 Feb; 117(7):2146-56. PubMed ID: 21076045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites.
    Marculescu R; Le T; Simon P; Jaeger U; Nadel B
    J Exp Med; 2002 Jan; 195(1):85-98. PubMed ID: 11781368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An antibody inhibitor of the LMO2-protein complex blocks its normal and tumorigenic functions.
    Nam CH; Lobato MN; Appert A; Drynan LF; Tanaka T; Rabbitts TH
    Oncogene; 2008 Aug; 27(36):4962-8. PubMed ID: 18438427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL.
    Dik WA; Nadel B; Przybylski GK; Asnafi V; Grabarczyk P; Navarro JM; Verhaaf B; Schmidt CA; Macintyre EA; van Dongen JJ; Langerak AW
    Blood; 2007 Jul; 110(1):388-92. PubMed ID: 17360939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the V(D)J recombination efficiency at lymphoid chromosomal translocation breakpoints.
    Raghavan SC; Kirsch IR; Lieber MR
    J Biol Chem; 2001 Aug; 276(31):29126-33. PubMed ID: 11390401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.
    Smith S; Tripathi R; Goodings C; Cleveland S; Mathias E; Hardaway JA; Elliott N; Yi Y; Chen X; Downing J; Mullighan C; Swing DA; Tessarollo L; Li L; Love P; Jenkins NA; Copeland NG; Thompson MA; Du Y; Davé UP
    PLoS One; 2014; 9(1):e85883. PubMed ID: 24465765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.
    Oram SH; Thoms JA; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Göttgens B
    Oncogene; 2010 Oct; 29(43):5796-808. PubMed ID: 20676125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.
    Ryu BY; Evans-Galea MV; Gray JT; Bodine DM; Persons DA; Nienhuis AW
    Blood; 2008 Feb; 111(4):1866-75. PubMed ID: 17991809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.